Literature DB >> 7861625

[Follow-up study of hepatic hemangiomas].

T Kobayashi1, M Kawano, Y Tomita, T Tamano, S Saegusa, M Horinaka, T Monma, M Oguma, N Yanagisawa, T Ohe.   

Abstract

Hepatic hemangioma is the most common benign tumor of the liver, but there are a few reports on chronological changes in size of hepatic hemangioma. To elucidate natural history of hepatic hemangioma, we evaluated consecutive ultrasonograms of 27 hemangiomas in 23 patients. Underlying liver disease in these 23 patients included seven cases with chronic hepatitis, five cases with liver cirrhosis and three cases with fatty liver. The remaining eight cases showed no evidence of liver disease. Follow-up period ranged 12 to 114 months (average 44). During the follow-up, six (22.2%) hemangiomas changed in size on US, which included three lesions with increase in size, one lesion with decrease in size and two lesions with spontaneous regression. Of 12 patients with chronic liver disease, only one patient showed significant change in the hemangioma size, which regressed spontaneously. These results showed that there was no case showing increase in size of hemangioma in patients with chronic liver disease. Thus, if clinically diagnosed hemangioma which tends to increase in size is detected on US or other imaging modalities in patients with chronic liver disease, aimed aspiration biopsy should be preferably performed considering the possibility of hepatocellular carcinoma.

Entities:  

Mesh:

Year:  1995        PMID: 7861625

Source DB:  PubMed          Journal:  Nihon Shokakibyo Gakkai Zasshi        ISSN: 0446-6586


  2 in total

1.  Sonographic characterization of 271 hepatic hemangiomas with typical appearance on CT imaging.

Authors:  Hiroaki Ito; Fumio Tsujimoto; Yasuo Nakajima; Gaku Igarashi; Takanori Okamura; Masaru Sakurai; Sachihiko Nobuoka; Takehito Otsubo
Journal:  J Med Ultrason (2001)       Date:  2012-01-12       Impact factor: 1.314

2.  Hepatic cavernous hemangioma in cirrhotic liver: imaging findings.

Authors:  J S Yu; K W Kim; M S Park; S W Yoon
Journal:  Korean J Radiol       Date:  2000 Oct-Dec       Impact factor: 3.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.